Merck and Inctye jointly carry out clinical trials of the drug combo treatment with favorable outcomes

Merck & Company, a major pharma giant and Incyte Corporation, reputed to be one of the key players in North America pharmaceutical industry, have achieved positive outcomes from their clinical experiments performed on the patients suffering from advanced stages of skin cancer. In these tests, both the firms combined their drugs, Keytruda and epacadostat, for treating the cancer patients. As per the data obtained from the trials, patients treated with the drug combination exhibited a response rate of nearly 56% and progression-free survival (PFS) of about 12.4 months. The PFS at the half-yearly stage was at 65%, 52% at 12 months, and 49% at 18 months.

As per the results derived from the clinical trials, thirty-five from among sixty-three skin cancer patients, who were treated with the medicine combination, had experienced the benefit of the combo treatment. The cancerous tumors from nine of these thirty-five patients were eliminated altogether after the combined drug treatment, while a partial response was witnessed in the rest of the patients.

The results derived from the recently conducted ECHO-202 trials has thus supported the earlier findings and implied that the new drug therapy used for treating patients suffering from advanced melanoma has bright future prospects. Statistics have displayed that the new combination biological therapy has indeed achieved high response rates and has depicted a substantial rise in the progression-free survival, which keytruda or epacasostat may not have been able to achieve successfully, if applied all by themselves.

For the record, Incyte Corporation’s Epacadostat has achieved a wide acclaim across the pharmaceutical sector, as a drug with high cancer treating potential. Its early trials on the cancer patients produced favorable outcomes that had a direct impact on the firm’s share prices. On the other hand, Merck’s keytruda has also brought about a substantial share price upswing, with its utilization in the treatment of advanced melanoma, bladder cancer, non-small cell lung cancer, kidney cancer, and head & neck cancer. Research is being carried on the drug to discover its ability of treating various other cancer types and measure the effects of the drug treatment after combining keytruda with its other counterparts.

This move will enable more pharma and biotechnology firms to follow suit. These breakthroughs will provide impetus to cancer research activities and help in bringing about a medical revolution, say experts. The paradigm shift is likely to help in the complete elimination of cancer in the decades to come.

About Author


Dhananjay Punekar

Dhananjay develops content for Market Size Forecasters. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted for a career in writing and now pens d...

Read More